Heritability of variation in glycaemic response to metformin

Zhou, Kaixin; Donnelly, Louise; Yang, Jian; Li, Miaoxin; Deshmukh, Harshal; Van Zuydam, Natalie; Ahlqvist, Emma; Spencer, Chris C.; Groop, Lief; Morris, Andrew D.; Colhoun, Helen M.; Sham, Pak C.; McCarthy, Mark I.; Palmer, Colin N.A.; Pearson, Ewan R.

Published in:
The Lancet: Diabetes and Endocrinology

DOI:
10.1016/S2213-8587(14)70050-6

Publication date:
2014

Document Version
Publisher's PDF, also known as Version of record

Link to publication in Discovery Research Portal

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis

Kaixin Zhou, Louise Donnelly, Jian Yang, Miaoxin Li, Harshal Deshmukh, Natalie Van Zuydam, Emma Ahlqvist, Colin N A Palmer, Ewan R Pearson

Summary

Background Metformin is a first-line oral agent used in the treatment of type 2 diabetes, but glycaemic response to this drug is highly variable. Understanding the genetic contribution to metformin response might increase the possibility of personalising metformin treatment. We aimed to establish the heritability of glycaemic response to metformin using the genome-wide complex trait analysis (GCTA) method.

Methods In this GCTA study, we obtained data about HbA1c concentrations before and during metformin treatment from patients in the Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) study, which includes a cohort of patients with type 2 diabetes and is linked to comprehensive clinical databases and genome-wide association study data. We applied the GCTA method to estimate heritability for four definitions of glycaemic response to metformin: absolute reduction in HbA1c; proportional reduction in HbA1c; adjusted reduction in HbA1c; and whether or not the target on-treatment HbA1c of less than 7% (53 mmol/mol) was achieved, with adjustment for baseline HbA1c and known clinical covariates. Chromosome-wise heritability estimation was used to obtain further information about the genetic architecture.

Findings 5386 individuals were included in the final dataset, of whom 2085 had enough clinical data to define glycaemic response to metformin. The heritability of glycaemic response to metformin varied by response phenotype, with a heritability of 34% (95% CI 1·68; p=0·022) for the absolute reduction in HbA1c, adjusted for pretreatment HbA1c. Chromosome-wise heritability estimates suggest that the genetic contribution is probably from individual variants scattered across the genome, which each have a small to moderate effect, rather than from a few loci that each have a large effect.

Interpretation Glycaemic response to metformin is heritable, thus glycaemic response to metformin is, in part, intrinsic to individual biological variation. Further genetic analysis might enable us to make better predictions for stratified medicine and to unravel new mechanisms of metformin action.

Funding Wellcome Trust.

Introduction Metformin is the recommended first-line oral agent for the treatment of hyperglycaemia in patients with type 2 diabetes, with more than 100 million users worldwide. Despite its impressive safety record and efficacy at the population level, the exact mechanism of metformin action is still elusive and patients’ glycaemic responses to metformin vary considerably.1 2 Understanding the source of such variation might help to identify patients most likely not to respond to metformin and could help to develop more effective agents by providing insight into the biological mechanism of metformin.

As with other complex traits, glycaemic response to metformin is probably determined by the interplay between genetic and environmental factors. Clinical variables such as BMI, drug adherence, and dosing only account for part of the variation.3 Pharmacogenetic studies have identified a few variants in genes affecting metformin action or its pharmacokinetics, yet these variants only account for a small fraction of the variation in metformin response.** Two possible explanations have been suggested for why so little genetic contribution to metformin response variability has been identified. First, it might be because the overall genetic contribution to variation in glycaemic response to metformin is low, with variation mainly due to environmental factors; in this case, trying to improve understanding of the genetic and biological variation in metformin response would have little value. A second explanation is that variation in response to metformin does have a large genetic component, but so far most of the variants with small to moderate effects have not been identified in genetic association studies because of inadequate statistical power; in this case, effort and resources should be invested in an effort to discover the genetic contribution to metformin response because it might enable a truly stratified approach to treatment with this drug. Estimation of the extent of genetic contribution to glycaemic response to metformin—often termed heritability—is of key importance to understand which of these explanations is correct.
Historically, the heritability of drug response has rarely been established, largely because of the impracticality of applying the traditional twin and family study designs to drug-response phenotypes; assembling sufficient family members with the same diagnosis who have received the same medication and have been assessed using the same treatment outcome is all but impossible. Alternative methods using population-based genome-wide association study (GWAS) data for heritability estimation have been developed.\(^2\)\(^-\)\(^11\) One of these methods, genome-wide complex trait analysis (GCTA), can estimate the distant genetic relationship between unrelated individuals using GWAS single-nucleotide polymorphism (SNP) data and can correlate the genetic similarity to the phenotypic similarity, thus partitioning the total phenotypic variance into genetic and environmental causes. Since modern GWAS arrays have good coverage of most common variants in the human genome, the variance estimated by the GCTA method—often referred to as chip heritability—is a good indicator of the additive genetic contribution from common SNPs.\(^12\) Because of the insufficient coverage of rare variants on GWAS arrays, heritability estimates by the GCTA method are often lower than the narrow-sense heritability derived from traditional twin and family studies. However, the GCTA method offers a more relevant and accurate estimate of drug-response heritability than other approaches that have been done using cell lines or animal models.\(^13\) In this study, we apply the GCTA method to GWAS data from the Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) study,\(^14\) with the aim of establishing the heritability of glycaemic response to metformin.

**Methods**

**Samples**

In this GCTA study, we used a bioresource linked to electronic health record data (GoDARTS) rather than a specific cohort developed to assess metformin pharmacogenetics. As part of the Wellcome Trust UK type 2 diabetes case-control collection, patients with type 2 diabetes in Tayside, Scotland, have been invited to give written informed consent for DNA collection since October, 1997. So far, nearly 10000 patients with type 2 diabetes have participated in the GoDARTS study.\(^14\) All clinical information about these patients can be obtained in an anonymised form from SCI-Diabetes (an electronic medical record for all patients with diabetes in Scotland) and these data are linked to biochemistry records and prescription encashments from 1992 onwards, giving a comprehensive longitudinal record of diabetes-related therapy. Participants consented for their data to be used in research into diabetes and related disorders, and this bioresource was approved by Tayside Regional Ethics Committee. The bioresource is now governed by Tayside Tissue Bank, which has approved the use of the bioresource for the study of metformin pharmacogenetics.

**Glycaemic response phenotypes**

We used HbA\(_1c\) concentration, which is a routinely measured clinical test of glycaemic control in patients with diabetes, to establish glycaemic response to metformin (appendix); fasting glucose or other non-HbA\(_1c\) measurements of glycaemic control are not available in the GoDARTS study. Pretreatment (baseline) HbA\(_1c\) was defined as the measurement closest to, and within 6 months of, the metformin start date (index date), whereas on-treatment HbA\(_1c\) was defined as the minimum recorded HbA\(_1c\) achieved within 18 months after the index date. We used four different response phenotypes: absolute reduction in HbA\(_1c\), which was the difference between baseline and on-treatment HbA\(_1c\); proportional reduction in HbA\(_1c\), which was the absolute reduction divided by baseline HbA\(_1c\); adjusted reduction in HbA\(_1c\), which was the residuals of absolute reduction adjusted by known clinical covariates such as baseline HbA\(_1c\), adherence, dose, creatinine clearance, and treatment group; and a dichotomous phenotype of whether or not the target on-treatment HbA\(_1c\) of <7% (53 mmol/mol) was achieved, with adjustment for baseline HbA\(_1c\) and known clinical covariates.

Patients who received metformin monotherapy used no other antidiabetic drugs in the 6 months before the index date or during the study period; sulfonylurea treatment was continued throughout the study period in patients who used metformin as an add-on therapy. The sulfonylurea dose was allowed to vary. Details about how the covariates are defined, and the response models, are outlined in the appendix.

**GWAS data and quality control**

GWAS data in the GoDARTS cohort were available from two previous studies. The Wellcome Trust Case Control Consortium 2 study (WTCCC2)\(^8\) genotyped 4134 patients with the Affymetrix 6.0 microarray (Santa Clara, CA, USA). The SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools (SUMMIT) study genotyped 3499 patients with the Illumina HumanOmniExpress microarray (Illumina, San Diego, CA, USA). Imputation to the HapMap3 panel—a database of common genetic variants that occur in human beings—and a stringent quality control pipeline were used to combine the two datasets and reduce the systematic discrepancy between the genotypes produced by the two microarrays and their corresponding calling algorithms (appendix).

We did two benchmark analyses with GCTA to validate the combined GWAS dataset. The first analysis showed that the heritability of human height was 46% (SE 6) in this cohort, which was consistent with previous estimates by studies applying the GCTA method.\(^15\) The second analysis estimated the heritability of a pseudo case-control phenotype assuming that samples from one genotyping platform were cases and those from the other
platform were controls. As expected, the estimated heritability of this dummy platform phenotype was less than 1% (SE 5), confirming that the original GWAS datasets were combined without introduction of artificial heritability.

Heritability estimation
We used GCTA version 1.11 to calculate the pair-wise genetic relationship between individuals and create the genetic relationship matrix.13 We then applied principal components analysis to all the SNPs to calculate the first ten eigenvectors, which we included as covariates in all the heritability estimation analyses to control for potential population structure. We then estimated univariate heritability of each drug-response phenotype by the restricted maximum likelihood method in GCTA, with sex and age at index date included as covariates.

Additionally, we used a bivariate analysis to jointly estimate the heritability of baseline HbA1c concentrations and the heritability of on-treatment HbA1c concentrations. The most informative parameter estimated from this bivariate analysis was the genetic correlation ($r_g$), which represents the proportion of variance shared between baseline HbA1c and on-treatment HbA1c concentrations that was contributed by common genetic determinants. The correlation between the residual variance is $r_e$, which represents, in part, contribution from environmental factors.

We established statistical significance using the likelihood-ratio test of specific hypothesis. We report the asymptotic 95% CI, which was calculated as 1.96 times the SE. Because the SEs of the parameter estimates were derived from first-order Taylor series expansions about the likelihood in GCTA, they might be biased for moderate study sample sizes,15 which at borderline levels of significance explains the discrepancy between p value and 95% CI reported.

Role of the funding source
The sponsor had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results
The combined dataset included 1150943 autosomal SNPs from 6992 patients. After filtering for cryptic relatedness, 5386 independent individuals were included in the final dataset. Of these, 2085 patients had sufficient clinical data to define their glycaemic response to metformin phenotypes. Table 1 summarises the main characteristics of the 2085 patients included in this study (for sample selection procedure see appendix), stratified by 1465 patients on metformin monotherapy and 620 patients who received metformin as add-on therapy to sulfonylureas.

Heritability ($h^2$) for baseline HbA1c was 29% (95% CI –1 to 60; p=0.048 for the null hypothesis of being non-heritable), increasing to 42% (10–73; p=0.0052) for on-treatment HbA1c (table 2). Baseline-adjusted on-treatment HbA1c had a heritability of 36% (95% CI 4–69; p=0.011). Of the four drug-response phenotypes, the model-adjusted reduction in HbA1c ($h^2=34\%$, 95% CI 1–68; p=0.022) and the ability to reach target HbA1c ($h^2=32\%$, –1 to 64; p=0.030) were the most heritable. The heritability estimates for absolute reduction in HbA1c ($h^2=23\%$, 95% CI –8 to 54) and proportional reduction in HbA1c ($h^2=20\%$, 95% CI –11 to 51) were smaller, and were not statistically significant (table 2).

To assess whether the genetic contribution to variation in response to metformin is driven by a few loci with a large effect or many loci with small effect, we did univariate heritability estimations for each chromosome separately for the two glycaemic response phenotypes that were significantly heritable. The genetic contribution to variation in response is distributed across several chromosomes (figure). When the proportion of variance in the model-adjusted reduction in HbA1c attributable to

<table>
<thead>
<tr>
<th>n</th>
<th>Heritability</th>
<th>95% CI</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline HbA1c</td>
<td>2085</td>
<td>29%</td>
<td>–1 to 60</td>
</tr>
<tr>
<td>On-treatment HbA1c</td>
<td>2085</td>
<td>42%</td>
<td>10 to 73</td>
</tr>
<tr>
<td>Achieved target HbA1c</td>
<td>1942</td>
<td>32%</td>
<td>–1 to 64</td>
</tr>
</tbody>
</table>

$p$-values are from likelihood tests of null hypothesis of heritability being 0. *The sample size was reduced to 1942 because some patients had a baseline HbA1c concentration of 7% or lower.

Table 2: Univariate heritability estimates of glycaemic response to metformin

Heritability ($h^2$) for baseline HbA1c was 29% (95% CI –1 to 60; p=0.048 for the null hypothesis of being non-heritable), increasing to 42% (10–73; p=0.0052) for on-treatment HbA1c (table 2). Baseline-adjusted on-treatment HbA1c had a heritability of 36% (95% CI 4–69; p=0.011). Of the four drug-response phenotypes, the model-adjusted reduction in HbA1c ($h^2=34\%$, 95% CI 1–68; p=0.022) and the ability to reach target HbA1c ($h^2=32\%$, –1 to 64; p=0.030) were the most heritable. The heritability estimates for absolute reduction in HbA1c ($h^2=23\%$, 95% CI –8 to 54) and proportional reduction in HbA1c ($h^2=20\%$, 95% CI –11 to 51) were smaller, and were not statistically significant (table 2).

To assess whether the genetic contribution to variation in response to metformin is driven by a few loci with a large effect or many loci with small effect, we did univariate heritability estimations for each chromosome separately for the two glycaemic response phenotypes that were significantly heritable. The genetic contribution to variation in response is distributed across several chromosomes (figure). When the proportion of variance in the model-adjusted reduction in HbA1c attributable to
each chromosome (chromosome-wise heritability) was regressed against the chromosome length, we noted a significant linear trend (p=0.037) for longer chromosomes to explain larger proportions of the variance. We also noted a similar trend (p=0.034) for achievement of target HbA1c.

Bivariate analysis of baseline and on-treatment HbA1c concentrations estimated a moderate genetic correlation (r_g) of 0.58 (95% CI 0.06–1.09) between these two traits (table 3). Likelihood ratio tests showed that the genetic correlation was statistically greater than 0 (p=0.053) and marginally less than 1 (p=0.097); where 0 would mean no genetic correlation and 1 would represent 100% genetic correlation.

Discussion
This study is, to our knowledge, the first to show that genetic differences contribute considerably to the variation noted in patients’ glycaemic response to metformin (panel). The heritability estimates for the frequently used definitions of glycaemic response range from 20% to 34%, suggesting that genetic variants are likely to have an important contribution to variation in
glycaemic response to metformin in patients with type 2 diabetes. In the context of GCTA estimates for other complex traits with well established heritability by family or twin studies, the point estimates are similar to GCTA estimates for schizophrenia \( (\hat{h}^2=23\% \text{ [SE 1]}) \) and Alzheimer’s disease \( (\hat{h}^2=30\% \text{ [SE 3]}) \), suggesting that genetic variants contribute to the variation in HbA\(_1c\) response to metformin to a similar extent.

We did the chromosome-wise heritability estimation to provide information about the genetic architecture of glycaemic response to metformin. Clearly, several variants across different chromosomes contribute to the metformin response variation. The finding that the contribution by an individual chromosome is significantly correlated to its length suggests that on each chromosome might be many variants with a small to moderate effect size rather than a few variants with major effect. This hypothesis is also supported by results of the metformin response GWAS, which reported that no individual variant explained a large proportion of the variance.\(^4\) Notably, the point estimates of chromosome-wise heritability all have large 95\% CIs and the estimates for each chromosome vary between the two different response phenotypes (figure). Thus, individual extreme values, such as the estimate of chromosome 1 in the analysis of model-adjusted reduction in HbA\(_1c\), could have had an undue effect on the reported trend.

In the univariate GCTA analysis we were able to assess whether different metformin response phenotypes are heritable. We do not have statistical power to conclude that one phenotype is more heritable than another, although the point estimates for the heritability of the response phenotypes that adjusted for the baseline HbA\(_1c\) were greater than for the unadjusted models. Because baseline HbA\(_1c\) has been well documented to have a major effect on the absolute reduction phenotype,\(^6\) the higher heritability estimates for baseline-adjusted phenotypes of metformin efficacy are likely to be a result of the successful adjustment for common environmental variance between baseline and on-treatment HbA\(_1c\) measurements. These adjusted phenotypes probably best address the pharmacogenetics of metformin when considering what factors are associated with the greatest reduction in HbA\(_1c\), for a given HbA\(_1c\) concentration before metformin initiation. An adjusted phenotype was used to successfully identify variants near the ATM locus that affect on-treatment HbA\(_1c\) but not baseline HbA\(_1c\).\(^4\) However, such definitions adjusted for baseline HbA\(_1c\) do capture some of the shared genetic component \( (\hat{r}_g) \) described above, and thus identified variants might reflect not only the response to metformin, but also the variance in HbA\(_1c\) per se. When considering what the biological determinants of response to metformin are, a better phenotype might be the unadjusted absolute reduction in HbA\(_1c\) because this measure does not capture any shared genetic contribution, only the variants with differential genetic effects between the HbA\(_1c\) before and after initiation of metformin treatment.\(^9\) Such an HbA\(_1c\) reduction model unadjusted for the baseline measure has been used in studies of statin pharmacogenetics.\(^20,21\) However, the heritability for the absolute reduction in HbA\(_1c\) did not achieve statistical significance in our study of response to metformin treatment.

We report a new application of the GCTA bivariate analysis in this drug-response study. This approach has advantages over univariate approaches because it does not make assumptions about the response model; rather, it uses a quantitative genetic approach to partition variance into genetic and environmental fractions that are shared and non-shared between two states or traits. The idea behind such an analysis is that intervention with metformin can change the physiological state of a patient. In the pretreatment state, a set of genetic and environmental factors determine the HbA\(_1c\) variation. The bivariate analysis can tell us not only how much of the HbA\(_1c\) variance is genetically determined in each state, but also how much of the genetically determined HbA\(_1c\) variance is shared between the two physiological states, as estimated by genetic correlation \( (\hat{r}_g) \). The shared variants that underlie the genetic correlation have the same effect on HbA\(_1c\) variation in the two states, and their genetic contribution to HbA\(_1c\) is not changed by metformin treatment. Thus an \( r_g \) of 1 would imply that metformin intervention does not change the genetic determinants of HbA\(_1c\) in the pretreatment and on-treatment state—ie, no pharmacogenetic effect occurs.\(^25\) By contrast, a low \( r_g \) would imply that the genetic determinants of HbA\(_1c\) are largely different before and after metformin treatment, hence a strong pharmacogenetic effect. In our analysis, the point estimate for the shared genetic contribution was 0.58, suggesting that around half of the genetic determinants contributing to baseline HbA\(_1c\) and on-treatment HbA\(_1c\) concentrations were shared, with half the genetic determinants differing between the baseline
and metformin treatment states; however, we do acknowledge that the 95% CI precludes a definitive conclusion of this bivariate analysis.

A key limitation of this study is the reasonably small sample size. However, the GoDARTS GWAS data used are from the largest metformin pharmacogenomic cohort done so far, including 2085 individuals who received metformin. Yet we still noted considerable 95% CIs for the heritability and genetic correlation estimates due to the limited sample size. Thus, despite having sufficient power to find that glycaemic response to metformin is a heritable trait, we do not have power to establish whether one drug response trait is more heritable than another. To do this, about 4450 patients would be needed to statistically differentiate two extremes of the estimated heritability of our four response traits. This shortfall in available data emphasises the importance of a consortium effort to assemble even more GWAS data, which will enable us to not only achieve more accurate estimates of heritability, but also discover more genetic variants that account for this heritability. The Metformin Genetics Consortium (MetGen) consists of research groups in Europe and the USA that have cohorts available for the study of the genetics of metformin. This consortium currently consists of about 5600 patients who have received metformin, and hopefully in the next 2–3 years additional academic and commercial clinical trial data and observational data might enable a GWAS of about 8000 individuals. Of note, interpretations of the heritability estimates from our current GCTA analyses can only be made in the context of the SNPs captured by the GWAS arrays. Contributions from the rare variants that are poorly covered by the GWAS panels will not form part of the heritability estimated by GCTA, but will remain in the environmental component. The observed environmental (residual) correlation ($r_e$) of 0–28 could be contributed by both environmental factors and shared rare genetic variants. Thus sequencing-based genomic studies with an emphasis on the rare drug-response variants are valid irrespective of the heritability estimates from GWAS SNPs.

In summary, using GWAS data from 2085 patients with type 2 diabetes, our analysis showed that genetic variants contributed to the variation in glycaemic response to metformin, with the heritability of metformin response estimated at up to 34% (95% CI 1–68; $p=0.022$). This result shows that a moderate proportion of the variance in glycaemic response is genetic, and represents underlying biological differences between individuals. The variants are likely to have a small-to-moderate effect and be scattered across the genome. So far, very little of the genetic contribution to metformin response has been identified; GWAS analyses with larger samples could find more genetic variants that enable better predictions to be made for personalised or stratified medicine, and unravel new mechanisms of metformin action in the reduction of hyperglycaemia.

Contributors
KZ, ERP, and CNAP designed the study and wrote the manuscript. HD, NVZ, EA, LG, MIMcC, and HMC undertook the SUMMIT (Surrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools) genome-wide association study (GWAS), were responsible for its quality control, and supplied the data. The Wellcome Trust Case Control Consortium 2 (WTCCC2) and CCS undertook the WTCCC2 GWAS and supplied the data. KZ analysed the data, and ERP and CNAP assisted in data interpretation. LD, JY, ML, and PCS assisted in the analysis and interpretation of the results. LD, JY, ML, PCS, HD, NVZ, EA, LG, MIMcC, HMC, CCS, and ADM edited the manuscript.

Declaration of interests
We declare that we have no competing interests.

Acknowledgments
We are grateful to all the participants who took part in this study, the general practitioners, the Scottish School of Primary Care for their help in recruiting the participants, and the whole team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. The Wellcome Trust provides support for Wellcome Trust UK type 2 diabetes case-control collection (GoDARTS; 099177/2/12/12) and informatics support is provided by the Chief Scientist Office. The Wellcome Trust funds the Scottish Health Informatics Programme, provides core support for the Wellcome Trust Centre for Human Genetics in Oxford and funds the Wellcome Trust Case Control Consortium 2 (084726/Z/08/Z). The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement number 115006 (JMI-SUMMIT); resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations companies’ kind contributions. PCS is supported by the Hong Kong Research Grants Council General Research Fund project (grants 777511 and 776513), and European Commission Seventh Framework Programme grant for the European Network of National Schizophrenia Networks Studying Gene-Environmental Interactions (EU-GEI). ERP holds a Wellcome Trust New Investigator award. MIMcC holds a National Institute for Health Research Senior Investigator award and a Wellcome Trust Senior Investigator award (098381). This research was specifically funded by the Wellcome Trust (092272/Z/10/Z) for a Henry Wellcome Post-Doctoral Fellowship to KZ.

References
9 So HC, Li M, Sham PC. Uncovering the total heritability explained by all true susceptibility variants in a genome-wide association study. *Genet Epidemiol* 2011; 35: 447–56.


